THERAPEUTIC APHERESIS IN KIDNEY TRANSPLANTATION; EMERGING TRENDS

https://storage.unitedwebnetwork.com/files/1099/0316308af8a50b95bd728463e69be7a1.pdf
THERAPEUTIC APHERESIS IN KIDNEY TRANSPLANTATION; EMERGING TRENDS
Chimezie
Okwuonu
Monarch Shah monarch.shah08@gmail.com University of Virginia Health Nephrology, Internal Medicine Charlottesville Virginia
Iram Rafique pmq9bf@uvahealth.org University of Virginia Health Nephrology, Internal Medicine Charlottesville, Virginia
Abdallah Abdelrazeq Aabdelraze@gmail.com University of Virginia Health Nephrology, Internal Medicine Charlottesville, Virginia
Korshie Dumor XAC7QN@uvahealth.org University of Virginia Health Nephrology, Internal Medicine Charlottesville, Virginia
Benjamin Silverberg BS4AV@uvahealth.org University of Virginia Health Nephrology, Internal Medicine Charlottesville, Virginia
Oluchi Chimezie oluchimezie85@gmail.com Federal Medical Centre Ophthalmology Umuahia, Abia State
Ijezie Chukwuonye chukwuonye4@yahoo.com Federal Medical Centre Nephrology, Internal Medicine Umuahia, Abia State
Efosa Oviasu efosaoviasu@uniben.edu University of Benin Teaching Hospital Nephrology, Internal Medicine Benin City
Rasheed Balogun rb8mh@uvahealth.org University of Virginia Health Nephrology, Internal Medicine Charlottesville, Virginia
 
 
 
 
 
 
The use of therapeutic apheresis (TA) either as adjunctive or stand alone treatment in kidney transplantation has increased over the years to become a leading indication. This study shows recent trends in indications for TA related to kidney transplantation, adverse events, grafts and patient survival in this cohort.
This was a retrospective cohort review of adults who underwent apheresis for kidney transplant indications from January 2017 to December 2022 at the University of Virginia Health, Virginia, USA. The data extracted included basic demographics, indications, number of procedures, procedure characteristics, serum ionized calcium and creatinine. Data was analysed using statistical package for social sciences (SPSS 2022 IBM Inc).
 
Antibody mediated rejection was the most common indication. Adverse events were mild and graft survival over the time points were remarkable
E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos